Company / R&D Expense
Rein Therapeutics, Inc. R&D Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$14.2M
FY2025
5-year range
$4.0M / $18.0M
FY2021-FY2025
Trend
+257.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense changed +257% YoY in FY2025, a notable deviation from the 8-year average annual change of +38%.
Based on SEC 10-K filings.
$14M in FY2025 with a 5-year CAGR of -4.2%.
Declined from $18M to $14M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -5.7%
- 5-Year CAGR
- -4.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -4.2%, indicating a declining trend.
- In FY2025, r&d expense increased 257.0% year-over-year.
- Peak r&d expense was recorded in FY2019.
- Lowest r&d expense in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $14.2M | +257.0% |
| FY2024 | $4.0M | -77.8% |
| FY2023 | $18.0M | +5.6% |
| FY2022 | $17.0M | +52.3% |
| FY2021 | $11.2M | -36.8% |
| FY2020 | $17.7M | -4.3% |
| FY2019 | $18.4M | +29.6% |
| FY2018 | $14.2M | +81.8% |
| FY2017 | $7.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026